目的：观察美多芭联合普拉克索治疗血管性帕金森综合征的临床效果。方法将53例血管性帕金森综合征患者随机分为对照组(26例)和治疗组(27例)。对照组给予美多芭治疗，治疗组在使用美多芭的基础上加用普拉克索，同时有适应证者给予拜阿司匹林治疗，疗程为12周，治疗前后采用帕金森量表进行评分并观察疗效。结果治疗组和对照组有效率分别为37.04%和30.77%，两组比较，差异无统计学意义(χ2=0.23，P﹥0.05)，两组帕金森病统一评分量表( UPDRS )比较，治疗前后评分均明显降低（ P﹤0.05），但两组治疗后UPDRS比较差异无显著性（ t=1.14，P﹥0.05）。结论美多芭及普拉克索可能对血管性帕金森综合征治疗均有效，但美多芭联合普拉克索较单用美多芭无明显差异。%Objective To observe the clinical efficacy of madopa combined with pramipexole in treating vascular parkinsonism. Methods 53 patients with vascular parkinsonism were randomly divided into the control group ( n=26 ) and the treatment group ( n=27 ) . The control group was given madopar, while on this basis the treatment group was added with pramipexole. At the same time those with indications were given bayaspirin. The treatment course in the two groups was 12 weeks. The Unified Parkinson's Disease Rating Scale ( UPDRS ) was adopted to conduct the evaluation before and after treatment. Results The effective rates after 12-week treatment in the treatment and control groups were 37. 04% and 30. 77% respectively, showing no statistical difference between the two groups (χ2=0. 23, P﹥0. 05 );the UPDRS scores after treatment in the two groups were significantly decreased compared with before treatment, there was statistical difference between before and after treatment ( P﹥0. 05 ) . But the UPDRS scores after treatment had no statistical difference between the two groups ( t=1. 14, P﹥0. 05 ) . Conclusion Madopar or pramipexole may be effective in the therapy of vascular parkinsonism, but madopar combined with pramipexole has no significantly difference than the single use of madopa.
展开▼
